30
Treatment
5.3. Antihypertensive Therapy for PAD
COR LOE
Recommendations
1 A
1. In patients with PAD and hypertension, antihypertensive
therapy should be administered to reduce the risk of MACE.
1 B-R
2. In patients with PAD and hypertension, a systolic blood
pressure (SBP) goal of <130 mm Hg and a diastolic blood
pressure target of <80 mm Hg is recommended.
1 B-R
3. In patients with PAD and hypertension, the selective use
of angiotensin-converting enzyme (ACE) inhibitors or
angiotensin-receptor blockers is recommended to reduce the
risk of MACE.
5.4. Smoking Cessation for PAD
COR LOE
Recommendations
1 A
1. Patients with PAD who smoke cigarettes or use any other
forms of tobacco should be advised at every visit to quit or
encouraged to maintain cessation.
1 A
2. Patients with PAD who smoke cigarettes or use any other forms
of tobacco should be assisted in developing a plan for quitting
that includes pharmacotherapy (ie, varenicline, bupropion,
and/or nicotine replacement therapies) combined with
counseling, and/or referral to a smoking cessation program.
1 B-NR
3. Patients with PAD should be advised to avoid exposure to
secondhand tobacco smoke in all indoor or enclosed spaces,
including work, home, transportation vehicles, and public
places.
5.5. Diabetes Management for PAD
COR LOE
Recommendations
1 A
1. In patients with PAD and type 2 diabetes, use of glucagon-
like peptide-1 agonists (liraglutide and semaglutide) and
sodium-glucose cotransporter-2 (SGLT-2) inhibitors
(canagliflozin, dapagliflozin, and empagliflozin) are effective
to reduce the risk of MACE.
1 C-EO
2. In patients with PAD, management of diabetes should be
coordinated among members of the health care team.
2b B-NR
3. In patients with PAD and diabetes, glycemic control may be
beneficial to improve limb outcomes.
